NOL | Jotup

IMUNON Reports 2023 Financial Results and Provides Business Update

Retrieved on:

Thursday, March 28, 2024

LAWRENCEVILLE, N.J., March 28, 2024 (GLOBE NEWSWIRE) -- IMUNON, Inc. (NASDAQ: IMNN), a clinical-stage drug-development company focused on developing DNA-mediated immuno-oncology therapies and next-generation vaccines, today reported financial results for the year ended December 31, 2023. The Company also provided an update on its clinical development programs with IMNN-001, a DNA-based interleukin-12 (IL-12) immunotherapy in Phase 2 clinical development for the treatment of first-line, locally advanced-stage ovarian cancer, and on its PlaCCine modality, a proprietary mono- or multi-cistronic DNA plasmid and a synthetic DNA delivery technology for the expression of pathogen antigens in preclinical studies for the development of next-generation vaccines.

Key Points:

“We remain on track to report topline results mid-year from the OVATION 2 Study with IMNN-001 in advanced ovarian cancer.
In September 2023, the Company announced interim PFS and OS data with IMNN-001 in its OVATION 2 Study.
The Company is hosting a conference call to provide a business update, discuss 2023 financial results and answer questions at 10:00 a.m. Eastern time today.
To participate in the call, please dial 866-777-2509 (Toll-Free/North America) or 412-317-5413 (International/Toll) and ask for the IMUNON 2023 Earnings Call.

IMUNON Receives $1.3 Million from Sale of its New Jersey Net Operating Losses

Retrieved on:

Monday, March 25, 2024

Transfer, Growth, Biotechnology, CFO, Research, NOL, Sale, Drug development, Workforce

LAWRENCEVILLE, N.J., March 25, 2024 (GLOBE NEWSWIRE) -- IMUNON, Inc. (NASDAQ: IMNN), a clinical-stage drug-development company focused on developing DNA-mediated immuno-oncology therapies and next-generation vaccines, announces receipt of $1.3 million in net cash proceeds from the sale of approximately $1.4 million of its unused New Jersey net operating losses (NOLs). The NOL sales are administered through the New Jersey Economic Development Authority’s (NJEDA) Technology Business Tax Certificate Transfer (NOL) program. This non-dilutive funding further strengthens the Company’s balance sheet.

Key Points:

LAWRENCEVILLE, N.J., March 25, 2024 (GLOBE NEWSWIRE) -- IMUNON , Inc. (NASDAQ: IMNN), a clinical-stage drug-development company focused on developing DNA-mediated immuno-oncology therapies and next-generation vaccines, announces receipt of $1.3 million in net cash proceeds from the sale of approximately $1.4 million of its unused New Jersey net operating losses (NOLs).
The NOL sales are administered through the New Jersey Economic Development Authority’s (NJEDA) Technology Business Tax Certificate Transfer (NOL) program.
“This program offered by the NJEDA provides IMUNON with investor-friendly ways to finance its clinical development programs,” said Jeffrey W. Church, IMUNON’s executive vice president and CFO.
IMUNON is one of several biotechnology/technology companies to qualify in this competitive process to share in the funding this year.

Destination XL Group, Inc. Reports Fiscal 2023 Fourth Quarter and Full-Year Financial Results

Retrieved on:

Thursday, March 21, 2024

E-commerce, Untuckit, Destination XL Group, Comparable, Tax, Growth, Male, Capital expenditure, History, NOL, Shoe, Investment, Interest, Depreciation, Income tax, DXL, Marketing, Corporation, Security (finance)

Comparable sales for the fourth quarter decreased 10.1% as compared to the fourth quarter of fiscal 2022.

Key Points:

Comparable sales for the fourth quarter decreased 10.1% as compared to the fourth quarter of fiscal 2022.
For the 14-week fourth quarter of fiscal 2023, total sales were $137.1 million as compared to $143.9 million for the 13-week fourth quarter of fiscal 2022.
SG&A expenses for the fourth quarter of fiscal 2023 were 38.5% of sales, compared with 37.8% in the fourth quarter of fiscal 2022.
Interest income for the fourth quarter of fiscal 2023 was $0.7 million, as compared to interest income of $0.1 million for the fourth quarter of fiscal 2022.

Cabaletta Bio Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update

Retrieved on:

Thursday, March 21, 2024

In October 2023, Cabaletta received Investigational New Drug (IND) application clearance from the U.S. Food and Drug Administration (FDA) for the Phase 1/2 RESET-SSc trial.

Key Points:

In October 2023, Cabaletta received Investigational New Drug (IND) application clearance from the U.S. Food and Drug Administration (FDA) for the Phase 1/2 RESET-SSc trial.
In November 2023, Cabaletta announced that its IND application for CABA-201 was allowed to proceed by the FDA for the Phase 1/2 RESET-MG trial.
Cabaletta anticipates reporting initial clinical data from the Phase 1/2 RESET-MG trial in the second half of 2024.
As of December 31, 2023, Cabaletta had cash, cash equivalents and short-term investments of $241.2 million, compared to $106.5 million as of December 31, 2022.

Hudson Global Reports 2023 Fourth Quarter and Full-Year Results

Retrieved on:

Thursday, March 14, 2024

RPO, Environment, Webcast, COVID-19, History, NOL, Table, OLD, GAAP, Workforce, Share repurchase, Video game

OLD GREENWICH, Conn., March 14, 2024 (GLOBE NEWSWIRE) -- Hudson Global, Inc. (Nasdaq: HSON), a leading global talent solutions company, announced today financial results for the fourth quarter and full year ended December 31, 2023.

Key Points:

OLD GREENWICH, Conn., March 14, 2024 (GLOBE NEWSWIRE) -- Hudson Global, Inc. (Nasdaq: HSON), a leading global talent solutions company, announced today financial results for the fourth quarter and full year ended December 31, 2023.
Jeff Eberwein, Chief Executive Officer at Hudson Global, said, "Our fourth quarter financial results continued to reflect the year-over-year impact of the slowdown in the US technology sector and as well as fourth quarter hiring delays at certain clients, which we expect to recover beginning in the second quarter of 2024.
Asia Pacific delivered adjusted EBITDA of $0.9 million in the fourth quarter of 2023 versus adjusted EBITDA of $2.1 million in the fourth quarter of 2022.
The Company generated $3.3 million in cash flow from operations in the fourth quarter of 2023 compared to $4.4 million in the fourth quarter of 2022.

Ocean Power Technologies, Inc. Announces Third Quarter Fiscal 2024 Results

Retrieved on:

Wednesday, March 13, 2024

MONROE TOWNSHIP, N.J., March 13, 2024 (GLOBE NEWSWIRE) -- Ocean Power Technologies, Inc. ("OPT" or "the Company") (NYSE American: OPTT), today announced financial results for its fiscal third quarter ended January 31, 2024 (“Q324”), including year over year revenue, gross profit, and pipeline growth.

Key Points:

MONROE TOWNSHIP, N.J., March 13, 2024 (GLOBE NEWSWIRE) -- Ocean Power Technologies, Inc. ("OPT" or "the Company") (NYSE American: OPTT), today announced financial results for its fiscal third quarter ended January 31, 2024 (“Q324”), including year over year revenue, gross profit, and pipeline growth.
The gross margin rate was 49.7% and 21.1%, for the nine months ended January 31, 2024, and 2023, respectively.
In February 2024, the Company received multiple orders for fully integrated WAM-V Unmanned Surface Vehicles (USVs) totaling over $1.25 million.
Operating expenses were $8.6 million in Q324, materially in-line with the second quarter of fiscal 2024 from and up from $6.8 million in Q323.

Kidpik and Nina Footwear Announce Entry Into Definitive Merger Agreement

Retrieved on:

Monday, April 1, 2024

Retail, Footwear, Online Retail, Fashion, Growth, NOL, Shoe, PIK, Dogcart, Mining

Kidpik Corp. (NASDAQ: PIK) (“Kidpik”), a kids’ online clothing subscription-based e-commerce company, and Nina Footwear Corp., a private company operating a brand specializing in women’s and kids’ dress shoes and accessories for special occasions (“Nina Footwear”), today announced that they have entered into a definitive merger agreement.

Key Points:

Kidpik Corp. (NASDAQ: PIK) (“Kidpik”), a kids’ online clothing subscription-based e-commerce company, and Nina Footwear Corp., a private company operating a brand specializing in women’s and kids’ dress shoes and accessories for special occasions (“Nina Footwear”), today announced that they have entered into a definitive merger agreement.
In connection with the merger, Nina Footwear stockholders will be issued shares of common stock of Kidpik such that upon closing thereof, Nina Footwear’s stockholders will own 80% of Kidpik’s outstanding common stock.
Kidpik is controlled by Mr. Ezra Dabah, the Chief Executive Officer, Chairman, and majority stockholder (67% beneficial owner) of Kidpik, who is also the Chief Executive Officer of Nina Footwear.
Mr. Dabah and his children own approximately 79.3% of Nina Footwear, and Mr. Dabah and his extended family own 100% of Nina Footwear.

Ocean Power Technologies Announces $1.2 million award from the New Jersey Economic Development Authority (NJEDA) Net Operating Loss (NOL) Program

Retrieved on:

Monday, January 29, 2024

Transfer, Research, NOL, OPT, Net, Ocean Power Technologies

MONROE TOWNSHIP, N.J., Jan. 29, 2024 (GLOBE NEWSWIRE) -- Ocean Power Technologies, Inc. (“OPT” or the “Company”) (NYSE American: OPTT), a leader in innovative and cost-effective low-carbon marine power, data, and service solutions, today announced it has been awarded approximately $1.2 million under the New Jersey Economic Development Authority (NJEDA) 2023 Technology Business Tax Certificate Transfer Program, commonly known as the Net Operating Loss (NOL) Program .

Key Points:

MONROE TOWNSHIP, N.J., Jan. 29, 2024 (GLOBE NEWSWIRE) -- Ocean Power Technologies, Inc. (“OPT” or the “Company”) (NYSE American: OPTT), a leader in innovative and cost-effective low-carbon marine power, data, and service solutions, today announced it has been awarded approximately $1.2 million under the New Jersey Economic Development Authority (NJEDA) 2023 Technology Business Tax Certificate Transfer Program, commonly known as the Net Operating Loss (NOL) Program .
This program enables technology and life sciences businesses in New Jersey to sell a percentage of their New Jersey net operating losses and unused research and development (R&D) tax credits to unrelated profitable corporations for cash.
OPT takes part in the NJEDA NOL program annually and this funding represents a significant resource as the Company continues to make progress on its previously announced path to profitability.
In addition, the receipt of this award demonstrates the potential value of the Company’s net operating losses and unused R&D tax credits and the need to preserve these potentially valuable assets and thereby preserve OPT’s ability to participate in future value enhancing monetization opportunities.

LivePerson Adopts Tax Benefits Preservation Plan To Protect Valuable Tax Assets

Retrieved on:

Monday, January 22, 2024

NOL, Person, 8-K, Rights, LPSN, Risk, Plan, Internal Revenue Code, LivePerson, Security (finance), Holding company

NEW YORK, Jan. 22, 2024 /PRNewswire/ -- LivePerson, Inc. ("LivePerson" or the "Company") (NASDAQ: LPSN), the global leader in enterprise conversations, today announced that its Board of Directors (the "Board") has unanimously adopted a tax benefits preservation plan (the "NOL Plan") designed to help preserve the full availability of the Company's net operating loss carryforwards ("NOLs").

Key Points:

The Company's NOL Plan is similar to NOL Plans adopted by other companies with significant NOL tax assets.
LivePerson intends to submit the NOL Plan for stockholder ratification at its 2024 Annual Meeting of Stockholders.
The NOL Plan is not designed to prevent any action that the Board determines is in the best interest of all LivePerson stockholders.
In connection with its adoption of the NOL Plan, the Board declared a dividend of one "right" under the NOL Plan for each outstanding share of LivePerson common stock.

Hudson Global Reports 2023 Third Quarter Results

Retrieved on:

Thursday, November 9, 2023

OLD, EBITDA, Webcast, Corporation, Acquisition, Share repurchase, NOL, GAAP, Table, Environment, Marex (British company), Cryptocurrency, Bookkeeping, Video game

OLD GREENWICH, Conn., Nov. 09, 2023 (GLOBE NEWSWIRE) -- Hudson Global, Inc. (Nasdaq: HSON) ("Hudson Global" or "the Company"), a leading global total talent solutions company, announced today financial results for the third quarter ended September 30, 2023.

Key Points:

OLD GREENWICH, Conn., Nov. 09, 2023 (GLOBE NEWSWIRE) -- Hudson Global, Inc. (Nasdaq: HSON) ("Hudson Global" or "the Company"), a leading global total talent solutions company, announced today financial results for the third quarter ended September 30, 2023.
“In the third quarter of 2023, a market-driven slowdown in hiring activity led to disappointing declines in revenue, adjusted net revenue, and adjusted EBITDA versus the prior year quarter," said Jeff Eberwein, Chief Executive Officer of Hudson Global.
Adjusted EBITDA was $0.2 million in the third quarter of 2023 compared to adjusted EBITDA of $0.4 million in the third quarter of 2022.
In the third quarter of 2023, the Company's corporate costs were $0.8 million, compared to $1.0 million in the prior year quarter.